qertbits.blogg.se - Harpoon therapeutics

It focuses on the research of novel class. Non-TLs: Liver, LN x2, Spleen, Bone, Brainįigure 9. Bleeding market cap since the start of June, Harpoon Therapeutics has found itself in the midst of a CEO transition. is a clinical-stage immunotherapy company, which engages in the development of antibodies. Remains on treatment with HPN328, beyond 28 weeks.Deepening of response over >6 months of treatment.New asymptomatic brain metastases identified at week 2.Overall response: PD Target Lesion response: PR Amount of Analyst Coverage Harpoon Therapeutics has only been the subject of 3 research reports in the past 90 days. The 9 analysts offering 12-month price forecasts for Harpoon Therapeutics Inc have a median target of 13.00, with a high estimate of 18.00 and a low. 65% decrease in sum of target lesion diameters. According to analysts consensus price target of 12.89, Harpoon Therapeutics has a forecasted upside of 510.8 from its current price of 2.11.60% cells positive for DL元 on IHC analysis of archival biopsy.

67-year-oldmale with extensive-stage SCLC.

Mean (SD) HPN328 Concentration-Time Profile (left) and Individual C max by Dose (right)

HPN328 exhibited linear PK, with dose-proportional increases in exposures at 0.135 to 12 mgįigure 3.

1/4 patients treated with 3.6mg C1D1 experienced Grade-1 CRS.

Grade-2CRS events occurred following C1D1 doses in 2/4 patients treated at 1.215mg, and in 1 patient receiving 3.6mg via intra-patient dose escalation.

Grade-3treatment-related anemia reported in 1 patient.

Grading per CTCAE v5.0, except Cytokine Release Syndrome (Grading per ASTCT 2019).

As of April 21 st, 2022, 18 patients were enrolled and treated with HPN328.‐ Retrospective analysis of tumor tissue for ‐ Evaluate preliminary anti-tumor activity HARP: Get the latest Harpoon Therapeutics stock price and detailed information including HARP news, historical charts and realtime prices. Refractory to Standard of Care (SOC) or no SCLC relapsed after platinum chemotherapy.Chiles Research Institute, Providence Cancer Institute, Portland, OR 8Medical College of Wisconsin, Milwaukee, WI 9Harpoon Therapeutics, South San Francisco, CA 10Dana Farber Cancer Institute, Boston, MAĭose Escalation / Expansion, Safety & PK Study in patients with small cell lungĬancer (SCLC) and other neuroendocrine malignancies Harpoon Therapeutics, Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of 5.91 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 47.76. Menon 8, Linda Santiago 9, Yifah Yaron 9, Himisha Beltran 10ġTennessee Oncology, Sarah Cannon Research Institute, Nashville, TN 2Roswell Park Comprehensive Cancer Center, Buffalo, NY 3Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 4Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH 5Memorial Sloan Kettering Cancer Center, New York, NY 6University of Colorado Anschutz Medical Campus, Aurora, CO 7Earle A.

Dy 2, Hirva Mamdani 3, Afshin Dowlati 4, Adam J. Interim results of an ongoing Phase 1/2 study of HPN328, a tri-specifichalf-life extended DL元-targetingT-cell engager, in patients with smallĬell lung cancer and other neuroendocrine cancers